AKT1 and cancer: Although clinical AKT-targeting inhibitors have been developed for treating AKT1 mutation-related cancers, they often target multiple AKT variants (AKT1, AKT2, and AKT3) and cause side effects like hyperglycemia, limiting their clinical usefulness.